Alger Small Cap Focus Fund Q3 2026 Portfolio UpdateSeeking Alpha · 1 day ago
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $304,272.41 in StockDefense World · 5 days ago
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewsWire · Oct 14, 2026
Adaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100GuruFocus · Oct 12, 2026
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Rated “Moderate Buy” by Sell-Side BrokeragesDefense World · Oct 12, 2026
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High – Still a Buy?Defense World · Oct 6, 2026Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | -$0.13 | -$0.25 | Miss |
| May 5, 2026 | -$0.16 | -$0.13 | Beat |
| Feb 5, 2026 | -$0.19 | -$0.09 | Beat |
| Nov 6, 2025 | -$0.18 | $0.06 | Beat |
| Aug 5, 2025 | -$0.24 | -$0.17 | Beat |
| May 5, 2025 | -$0.34 | -$0.20 | Beat |